Board of Directors

Scott Stevens

Founder and Chairman of the Board

Mr. Stevens is a career entrepreneur, investor and operator with over 20 years of experience. Most recently he founded Applied BioSciences Corp. (OTCQB: APPB). He previously served as a Managing Director at JAT Capital, L.P. managing a $1 billion portfolio focused on TMT, and a Portfolio Manager at S.A.C. Capital Advisors, L.P. since 2012 running a $250mm TMT Portfolio. Scott also served as the Co-Founder and Head of Research at Strata Capital Management from 2006-2012 where he was responsible for the investment process, idea generation, internal screens and analyst management.  

Before joining Strata, Scott worked at Ivory Capital Group LLC, a long/short equity fund, from 2004-2006, with a primary focus in managing the firm’s technology portfolio. He was responsible for idea generation, investment analysis, position-sizing, position-hedging and trade recommendations. Prior to that, he worked at Coatue Capital L.L.C from 2001-2004, a fundamental value based long/short equity fund where he helped to build the fund over a three-year period and assisted in the creation of many of the firm’s investing templates and practices. Prior to Coatue, Scott worked at Merrill Lynch & Co. 1998-2001 as an Analyst in the Mergers & Acquisitions Group where he completed over $20B of transactions in various sectors including aerospace/defense, media, healthcare and energy. He also worked in Merrill’s Global Communications Group where he served as an Analyst for the Taurus Fund, a private equity fund specializing in early to mid-stage telecommunications investments.

Scott graduated from the University of Michigan (BA Economics).

Dr. Raymond W. Urbanski MD, Ph.D.

Chief Executive Officer and Director

Dr. Raymond W. Urbanski, M.D., Ph.D. has been the Chief Executive Officer (CEO) of Applied Biosciences since May 1, 2019. He is a well-established industry leading expert with an impressive background in clinical, research, and pharmaceutical industry expertise across oncology, cardiology, endocrinology, and immunology. Over the course of his career spanning over 20 years, Dr. Urbanski has been responsible for developing and overseeing numerous clinical studies, including Phase 3b and Phase 4 studies, for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremilimumab.

Dr. Urbanski joined the Applied BioSciences team having most recently served as Chief Medical Officer and then CEO of GT Biopharma, Inc. (OTCQB: GTBP). Prior to GT Biopharma, Dr. Urbanski served as Chief Medical Officer at Mannkind (NASDAQ: MNKD), Mylan, Inc. (NASDAQ: MYL) and at Metabolex, Inc. While at GT Biopharma and MannKind, Dr. Urbanski was responsible for establishing the R&D organization and leading the overall drug development activities. Most notably in his career, Dr. Urbanski spent eight years with Pfizer (NYSE: PFE), where he held several positions, including Vice President and Chief Medical Officer of the Established Products Business Unit, Senior Medical Director of Oncology Clinical R&D, Senior Medical Director of Breast Cancer Products and Medical Director of Diversified Products. While serving at Pfizer, his leadership accomplishments included the successful development and approval of numerous [actual number?] new drugs and new indications across several therapeutic areas. Prior to serving at Pfizer, Dr. Urbanski served as Vice President and Chief Medical Officer at Suntory Pharmaceuticals, Inc.

Dr. Urbanski received his PhD in Pharmacology from the University of Medicine and Dentistry of New Jersey, Graduate School of Biomedical Sciences (GSBS) and his MD from the New Jersey Medical School.  He was awarded the GSBS Fellowship Award and the Michael W Pozen scholarship during his graduate studies and medical education, respectively. Dr. Urbanski completed his residency and research training at Thomas Jefferson University Hospital in Philadelphia as part of the American Board of Internal Medicine’s Clinical Investigator Pathway. Following his training he joined a large internal medicine practice in Philadelphia while co-founding and serving as President of Clinical Studies Associates (CSA, Inc.), an organization involved in the conduct of clinical studies. During his time in practice and early on in his career in the pharmaceutical industry he held roles of Sub-Investigator, Principle Investigator, and Medical Director in a large number of clinical trials across multiple therapeutic areas. Many led to peer-reviewed publications as well as presentations at national and international conferences.

Chris Bridges


Chris Bridges has served as our President since February 10, 2017, and as a director since March 9, 2017. Mr. Bridges has served as the Chief Executive Officer of Vessix Inx, a virtual payment systems business which provides payment services designed for the aviation industry, since January 2013. From January 2009 until September 2013, Mr. Bridges served as a director of Banctek Solutions, which provides merchant bankcard processing services to all types of merchants. From January 2005 until January 2008, Mr. Bridges was Executive Vice President - Acquisitions at PRS Assets, of Denver, Colorado.

Michael Beaubaire, M.D.


Dr. Beaubaire has been the Principal of Beaubaire LLC since 2002. Beaubaire LLC is a life science and healthcare advisory company providing investing and portfolio management, business development execution, strategic consulting and capital raising services to established equity funds, consulting organizations and start-up companies. From June 2017 to July 2019, Dr. Beaubaire served as Chief Executive Officer and a director of Immunomodulation Inc., a privately held biopharmaceutical company. Dr. Beaubaire also served as Chair of the Scientific Advisory Board and Co-Head of Healthcare Investing, of Lincoln Park Capital, a privately held investment company, from 2011 to 2018. In 1990, Dr. Beaubaire graduated with a BA (Biological Basis of Behavior) and a BS (Economics) from the University of Pennsylvania, and graduated with a MD from Northwestern School of Medicine in 1995.